Itron (ITRI) Q2 EPS Jumps 34%

Itron (NASDAQ:ITRI) reported strong Q2 2025 earnings, with non-GAAP EPS of $1.62 significantly beating estimates by 20% and record gross margin of 36.9% driving robust profitability and a doubling of free cash flow to $91 million. Despite a slight GAAP revenue miss at $607 million, down 0.3% year-over-year, the company demonstrated disciplined cost management and a favorable product mix, particularly with 9% growth in its recurring Outcomes software segment. The balance sheet strengthened, and a $4.5 billion backlog provides revenue visibility, supporting updated FY2025 non-GAAP EPS guidance of $6.00-$6.20, though persistent trade policy and supply chain risks remain notable.

Analysis

Itron's (NASDAQ:ITRI) second quarter 2025 results illustrate a successful strategic focus on profitability and operational execution, even as top-line growth stagnated. The company delivered a significant non-GAAP EPS of $1.62, beating consensus estimates by 20% and marking a 33.9% year-over-year increase. This outperformance was primarily driven by a record gross margin, which expanded 2.3 percentage points to 36.9%, fueled by a favorable product mix and disciplined cost management. This margin strength translated directly into robust cash generation, with non-GAAP free cash flow more than doubling to $91 million. However, GAAP revenue of $607 million was effectively flat, declining 0.3% year-over-year and slightly missing expectations. A breakdown of segment performance reveals a deliberate pivot: while legacy Device Solutions revenue fell 5%, the strategic Outcomes segment, comprising software and recurring services, grew 9%. The company's balance sheet strengthened with reduced debt, and a $4.5 billion backlog provides medium-term revenue visibility, supporting updated full-year non-GAAP EPS guidance of $6.00 to $6.20. Despite these strengths, management has flagged a notable $15 million EBITDA exposure to tariffs for FY2025, presenting a material risk for the second half of the year.

Key Decisions for Investors

• Investors should weigh the company's demonstrated operational leverage, evidenced by the record gross margin and significant EPS beat, against the flat year-over-year revenue.
• The 9% growth in the high-margin, recurring-revenue Outcomes segment is a key positive catalyst, and its continued expansion should be monitored as a primary indicator of the success of Itron's strategic pivot.
• It is prudent to factor in the explicitly stated $15 million EBITDA risk from potential tariffs for FY2025, which could create headwinds for profitability in the latter half of the year.
• While the $4.5 billion backlog offers solid revenue visibility, the lower sequential bookings of $454 million in Q2 warrant attention as a potential leading indicator for future growth momentum.